8229 Boone Boulevard
Vienna, VA 22182
703 506 9460
|Mr. Geert R. Kersten Esq.||Chief Exec. & Financial Officer, Treasurer and Director||681.99k||N/A||1959|
|Ms. Patricia B. Prichep||Sr. VP of Operations & Corp. Sec.||286.03k||N/A||1951|
|Dr. Eyal Talor Ph.D.||Chief Scientific Officer||340.59k||N/A||1956|
|Dr. Daniel H. Zimmerman Ph.D.||Sr. VP of Research & Cellular Immunology||262.86k||N/A||1941|
|Mr. John Cipriano||Sr. VP of Regulatory Affairs||239.1k||N/A||1942|
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
CEL-SCI Corporation’s ISS governance QualityScore as of 1 May 2023 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder rights: 6; Compensation: 10.